Menu Search
Equities

Immunitybio Inc

IBRX:NSQ

Immunitybio Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)4.95
  • Today's Change-0.50 / -9.17%
  • Shares traded10.31m
  • 1 Year change+59.16%
  • Beta0.7656
Data delayed at least 15 minutes, as of Nov 12 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Immunitybio Inc had net income fall 40.00% from a loss of 416.57m to a larger loss of 583.20m despite a 159.17% increase in revenues from 240.00k to 622.00k.
Gross margin--
Net profit margin-45,701.07%
Operating margin-27,527.06%
Return on assets-162.54%
Return on equity--
Return on investment-1,927.61%
More ▼

Cash flow in USDView more

In 2023, Immunitybio Inc increased its cash reserves by 153.21%, or 160.82m. Cash Flow from Financing totalled 558.34m or 89,765.43% of revenues. In addition the company used 366.76m for operations while cash used for investing totalled 30.47m.
Cash flow per share-0.9172
Price/Cash flow per share--
Book value per share-1.01
Tangible book value per share-1.03
More ▼

Balance sheet in USDView more

Immunitybio Inc appears to have a weak balance sheet, highlighted by its negative owner's equity. Additionally, this company's debt load is greater than its assets while day-to-day operations are losing money. Immunitybio Inc has considerable financial risk.
Current ratio3.91
Quick ratio3.88
Total debt/total equity--
Total debt/total capital3.69
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.